Publications by authors named "Lisa Roberts-Rapp"

Claim this Profile
P
Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer.
Jair Bar, Mona H Cai, Yookyung Christy Choi, Shobhit Baijal, Weilong Zhao, Lisa Roberts-Rapp

Acta Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
James M Cleary, Emiliano Calvo, Victor Moreno, Dejan Juric, Geoffrey I Shapiro, Lisa Roberts-Rapp

Invest New Drugs· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma.
Andrew B Lassman, Kenneth D Aldape, Peter J Ansell, Earle Bain, Walter J Curran, Lisa Roberts-Rapp

J Neurooncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Biomarker Assays for : Implications for Precision Medicine in Patients with Glioblastoma.
Andrew B Lassman, Lisa Roberts-Rapp, Irina Sokolova, Minghao Song, Ekaterina Pestova

Clin Cancer Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Andrew B Lassman, Martin J van den Bent, Hui K Gan, David A Reardon, Priya Kumthekar, Lisa Roberts-Rapp

Neuro Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Hui K Gan, David A Reardon, Andrew B Lassman, Ryan Merrell, Martin van den Bent, Lisa A Roberts-Rapp

Neuro Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Glenwood D Goss, Everett E Vokes, Michael S Gordon, Leena Gandhi, Kyriakos P Papadopoulos, Lisa A Roberts-Rapp

Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
Martin van den Bent, Hui K Gan, Andrew B Lassman, Priya Kumthekar, Ryan Merrell, Lisa Roberts-Rapp

Cancer Chemother Pharmacol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
David A Reardon, Andrew B Lassman, Martin van den Bent, Priya Kumthekar, Ryan Merrell, Lisa Roberts-Rapp

Neuro Oncol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Stephen K Tahir, Morey L Smith, Paul Hessler, Lisa Roberts Rapp, Kenneth B Idler

BMC Cancer· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.
Xiaoyu Lin, Xiaoli Huang, Tamar Uziel, Paul Hessler, Daniel H Albert, Lisa A Roberts-Rapp

Mol Cancer Ther· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
Guillermo Garcia-Manero, Raoul Tibes, Tapan Kadia, Hagop Kantarjian, Martha Arellano, Lisa Roberts-Rapp

Invest New Drugs· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.
Yu Xiao, Paul Nimmer, George S Sheppard, Milan Bruncko, Paul Hessler, Lisa Roberts-Rapp

Mol Cancer Ther· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiplex analysis of anti-apoptotic BCL2 family and caspase 3 activation by microbead arrays.
Lloyd T Lam, Lisa Roberts-Rapp

Assay Drug Dev Technol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis